ArticleProceedings of the National Academy of Sciences of the United States of America2018
PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Identification of GSE1 as a PAX5 fusion partner and characterization of PAX5 fusion signature in B-cell acute lymphoblastic leukaemia.British journal of haematology · 2026Article
- Signals from the bone marrow B cell niches shape pre-leukemic fate in a murine model of B cell acute lymphoblastic leukemia.Oncogene · 2026Article
- Two-way inhibition of PAX5 transcriptional activity by PAX5::CBFA2T3.FEBS open bio · 2025Article
- In vivo CRISPR screening reveals cooperation of KMT2D and TP53 deficiencies in B-cell lymphomagenesis.Blood advances · 2025Article
- The IL7 receptor and the RAG complex are required for the onset of B-cell acute lymphoblastic leukemia.Blood advances · 2025Article
- PAX Family, Master Regulator in Cancer.Diagnostics (Basel, Switzerland) · 2025Review
- Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency.International journal of molecular sciences · 2024Review
- Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL.The Journal of experimental medicine · 2024Article
- Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation.iScience · 2023Article
- Lessons from mouse models in the impact of risk factors on the genesis of childhood B-cell leukemia.Frontiers in immunology · 2023Review
- The Pleiotropy ofInternational journal of molecular sciences · 2022Review
- Childhood B-Cell Preleukemia Mouse Modeling.International journal of molecular sciences · 2022Review
- In vivo impact of JAK3 A573V mutation revealed using zebrafish.Cellular and molecular life sciences : CMLS · 2022Article
- Review
- Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells.Cancers · 2021Review
- PAQR3 inhibits proliferation and aggravates ferroptosis in acute lymphoblastic leukemia through modulation Nrf2 stability.Immunity, inflammation and disease · 2021Article
- Risk Factors for Childhood Leukemia: Radiation and Beyond.Frontiers in public health · 2021Review
- Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas.Frontiers in immunology · 2021Review
- Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient.International journal of hematology · 2020Article
- Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome.Leukemia · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 1 country.
Laura JamrogCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier (UPS), 31037 Toulouse, France.
Guillaume CheminInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique (CNRS), UPS, 31077 Toulouse, France.
Vincent FregonaCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier (UPS), 31037 Toulouse, France.
Lucie CosterLaboratoire d'Hématologie, Centre Hospitalier Universitaire (CHU) de Toulouse, 31000 Toulouse, France.
Marlène PasquetDepartment of Pediatric Hematology, CHU de Toulouse, 31000 Toulouse, France.
Chloé OudinetInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique (CNRS), UPS, 31077 Toulouse, France.
Nelly RouquiéCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier (UPS), 31037 Toulouse, France.
Naïs PradeCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier (UPS), 31037 Toulouse, France.
Stéphanie LagardeCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier (UPS), 31037 Toulouse, France.
Charlotte CressonCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier (UPS), 31037 Toulouse, France.
Sylvie HébrardCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier (UPS), 31037 Toulouse, France.
Ngoc Sa Nguyen HuuInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique (CNRS), UPS, 31077 Toulouse, France.
Marina BousquetCRCT, INSERM, UPS, ERL5294 CNRS, Laboratoire d'Excellence Toulouse Cancer (TOUCAN), 31037 Toulouse, France.
Cathy QuelenCRCT, INSERM, UPS, ERL5294 CNRS, Laboratoire d'Excellence Toulouse Cancer (TOUCAN), 31037 Toulouse, France.
Pierre BroussetCRCT, INSERM, UPS, ERL5294 CNRS, Laboratoire d'Excellence Toulouse Cancer (TOUCAN), 31037 Toulouse, France.
Stéphane J C ManciniAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes (IPC), Centre de Recherche en Cancérologie de Marseille (CRCM), 13009 Marseille, France.
Eric DelabesseCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier (UPS), 31037 Toulouse, France.
Ahmed Amine KhamlichiInstitut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, Centre National de la Recherche Scientifique (CNRS), UPS, 31077 Toulouse, France.
Bastien GerbyCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier (UPS), 31037 Toulouse, France; bastien.gerby@inserm.fr cyril.broccardo@inserm.fr.
Cyril BroccardoCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier (UPS), 31037 Toulouse, France; bastien.gerby@inserm.fr cyril.broccardo@inserm.fr.
Université Toulouse III - Paul Sabatier · FRCentre de Recherche en Cancérologie de Toulouse · FRCentre Hospitalier Universitaire de Toulouse · FRCentre National de la Recherche Scientifique · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FRInserm · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsB-LymphocytesElastinGene Expression Regulation, LeukemicGene Knock-In TechniquesJanus Kinase 3Mice, TransgenicMutationNeoplasms, ExperimentalOncogene Proteins, FusionPAX5 Transcription FactorPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)ElastinHras protein, mouseJak3 protein, mouseJanus Kinase 3Oncogene Proteins, FusionPAX5 protein, humanPAX5 Transcription FactorProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)Ptpn11 protein, mouseB-cell acute lymphoblastic leukemiaengineered mouse modelsleukemia initiationoncogenic transformationPAX5 fusion proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.